Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pathway Genomics Remains In FDA Crosshairs For Genetic Testing Service

This article was originally published in The Gray Sheet

Executive Summary

An untitled letter from FDA targets Pathway Genomics' recent launch of a cancer screening assay that FDA says is being marketed directly to consumers without proper FDA review.

Advertisement

Related Content

FDA, 23andMe Open Up Market Pathway For DTC Genetics
FDA To Regulate Direct-To-Consumer Genetic Tests
FDA Cites Long-Term Precedent In Blocking Retail Genetic Screening Plans

Topics

Advertisement
UsernamePublicRestriction

Register

MT034233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel